摘要
目的:观察降脂护肝系列胶囊治疗非酒精性脂肪性肝炎的临床疗效。方法:治疗组100例,采用辨证分型与辨病相结合的方法,分别用降脂护肝Ⅰ、Ⅱ、Ⅲ号胶囊治疗;对照组60例用烟酸肌醇脂片及肝泰乐治疗。两组均用药8周,治疗期间不予其他护肝、降酶和降血脂类药物,观察治疗前后患者血清ALT、AST、TCh、TG、PⅢP、LN、HA、Ⅳ-C的变化,肝脏B超或CT的结果变化以及临床症状、体征的变化。结果:治疗组的临床显效率为65%,对照组为35(,差异有非常显著性意义(P<0.01)。治疗组总有效率94(,对照组为58.3(,差异有显著性意义(P<0.05);治疗组治疗前后ALT、AST、TCh、TG、PⅢP、LN、HA、Ⅳ-C等生化检测结果比较,差异有非常显著性意义(P<0.01)。治疗后两组ALT、GGT、TCh、TG等值比较,差异有非常显著性意义(P<0.01)。结论:降脂护肝胶囊治疗非酒精性脂肪性肝炎疗效良好,有护肝、降酶和抗肝纤维化作用。
Objective:To observe the clinical effect of serial Jiangzhi Hugan capsule(JZHGC)on nonalcoholic steatohepatitis(NASH).Methods:One hundred patients in the treatment group were given JZHGCⅠ,Ⅱ and Ⅲ respectively on the basis of syndrome differentiation combined with disease differentiation;Sixty patients in the control group was treated with tabellae inositoli nicotinatis and glucuro lactone tablets.After they were treated for 8 weeks without other drugs for protecting liver function,reducing aminotransferase and lowering lipid.Changes of ALT,AST,TCh,TG,PⅢP,LN,HA,Ⅳ-C,B-ultrasound,CT,clinical symptoms and signs before and after treatment were observed.Results:The distinct effective rate in the treatment group and in the control group were 65% and 35% respectively(P 0.01);The total effective rate in the treatment group and in the control group were 94% and 58.3 %respectively;There were also significant differences in ALT,GGT,TCh,TG between the two groups after treatment(P 0.01).After treatment,changes of biochemical items such as ALT,AST,TBil,TCh,TG,PⅢP,LN,HA,Ⅳ-C in the treatment group were significant(P 0.01).Conclusion: JZHGC can protect liver function,reduce aminotransferase and treat liver fibrosis.
出处
《中西医结合肝病杂志》
CAS
2011年第2期88-89,101,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
关键词
非酒精性脂肪性肝炎
降脂护肝胶囊
临床研究
nonalcoholic steatohepatitis
Jiangzhi Hugan capsule
clinical research